Lataa...
The clinical utility of tumor mutational burden in non-small cell lung cancer
Despite advances made during the last two decades, lung cancer remains the leading cause of cancer-related death worldwide. Recently, immune checkpoint inhibitors (ICIs) became available for the treatment of advanced non-small cell lung cancer (NSCLC) patients. Although ICIs showed a survival advant...
Tallennettuna:
| Julkaisussa: | Transl Lung Cancer Res |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
AME Publishing Company
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6249623/ https://ncbi.nlm.nih.gov/pubmed/30505708 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr.2018.10.08 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|